Brokerages Set Blueprint Medicines Co. (NASDAQ:BPMC) Target Price at $124.95

Blueprint Medicines Co. (NASDAQ:BPMC) has been given an average rating of “Moderate Buy” by the twenty-three analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation, fifteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $124.95.

Several brokerages have weighed in on BPMC. Wolfe Research began coverage on Blueprint Medicines in a research report on Tuesday, March 18th. They issued an “outperform” rating on the stock. Scotiabank initiated coverage on Blueprint Medicines in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $150.00 target price on the stock. StockNews.com cut Blueprint Medicines from a “hold” rating to a “sell” rating in a research note on Monday, March 3rd. Stephens reissued an “overweight” rating and issued a $140.00 price target on shares of Blueprint Medicines in a research note on Thursday, January 2nd. Finally, Needham & Company LLC reissued a “buy” rating and issued a $133.00 price target on shares of Blueprint Medicines in a research note on Thursday, February 13th.

Blueprint Medicines Price Performance

Shares of NASDAQ BPMC opened at $88.72 on Friday. Blueprint Medicines has a 1-year low of $80.68 and a 1-year high of $121.90. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The business’s fifty day moving average price is $99.47 and its two-hundred day moving average price is $93.89. The firm has a market capitalization of $5.67 billion, a PE ratio of -82.15 and a beta of 0.58.

Blueprint Medicines (NASDAQ:BPMC) last issued its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. On average, research analysts expect that Blueprint Medicines will post -1.28 EPS for the current year.

Insider Activity

In other news, Director Jeffrey W. Albers sold 5,000 shares of the company’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $102.28, for a total transaction of $511,400.00. Following the completion of the sale, the director now directly owns 157,557 shares of the company’s stock, valued at $16,114,929.96. This represents a 3.08 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Ariel Hurley sold 2,250 shares of the company’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $100.00, for a total value of $225,000.00. Following the sale, the insider now directly owns 14,967 shares of the company’s stock, valued at approximately $1,496,700. This represents a 13.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 29,334 shares of company stock valued at $3,103,512 over the last three months. Insiders own 4.21% of the company’s stock.

Institutional Investors Weigh In On Blueprint Medicines

Several hedge funds have recently bought and sold shares of BPMC. Swiss National Bank lifted its stake in Blueprint Medicines by 1.6% in the 3rd quarter. Swiss National Bank now owns 116,200 shares of the biotechnology company’s stock worth $10,748,000 after acquiring an additional 1,800 shares in the last quarter. Segall Bryant & Hamill LLC lifted its stake in Blueprint Medicines by 11.6% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 141,622 shares of the biotechnology company’s stock worth $13,100,000 after acquiring an additional 14,668 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Blueprint Medicines in the 3rd quarter worth about $475,000. Advisors Asset Management Inc. lifted its stake in Blueprint Medicines by 17.6% in the 3rd quarter. Advisors Asset Management Inc. now owns 5,054 shares of the biotechnology company’s stock worth $467,000 after acquiring an additional 756 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new stake in Blueprint Medicines in the 3rd quarter worth about $6,465,000.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.